Physician profile
Roger Willette
NPI 1831138445
$1,191.32
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $298 · 2020: $118 · 2021: $330 · 2022: $232 · 2023: $196 · 2024: $16.94.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $213.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $166.87 | 2019-2024 | Airsupra |
| Janssen Pharmaceuticals, INC | $133.10 | 2019-2023 | Spravato, Xarelto |
| Pfizer INC. | $87.60 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $85.45 | 2021-2022 | |
| Astellas Pharma US INC | $78.41 | 2019-2023 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.22 | 2021-2023 | Xifaxan, Trulance |
| Abbvie INC. | $56.99 | 2021 | |
| Currax Pharmaceuticals LLC | $54.19 | 2020-2021 | |
| Glaxosmithkline, LLC. | $52.91 | 2023 | Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $49.68 | 2022-2023 | |
| Optinose US, INC. | $45.30 | 2019-2020 | |
| Novo Nordisk INC | $41.58 | 2019-2022 | |
| Lilly USA, LLC | $41.47 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $35.18 | 2021 | |
| Nalpropion Pharmaceuticals LLC | $28.39 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $25.50 | 2019 | |
| Xeris Pharmaceuticals, INC. | $24.43 | 2022 | |
| Esperion Therapeutics, INC. | $22.12 | 2021 | |
| Exact Sciences Corporation | $22.11 | 2023 | Cologuard Collection Kit |
| Antares Pharma, INC. | $21.97 | 2022 | |
| Amgen INC. | $19.67 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $15.00 | 2020 | |
| Strongbridge US INC. | $13.29 | 2020 | |
| Arbor Pharmaceuticals, INC. | $11.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Willette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.